{"Trastuzumab": [0], "emtansine": [1, 59, 136, 182, 297], "is": [2], "the": [3, 44, 102, 215, 255, 282, 285, 295, 322], "current": [4], "standard": [5], "treatment": [6, 24], "for": [7, 139, 185], "patients": [8, 61, 156, 216, 283, 309], "with": [9, 25, 55, 62, 69, 124, 134, 170, 180, 246, 251, 310, 317, 345, 350], "human": [10], "epidermal": [11], "growth": [12], "factor": [13], "receptor": [14], "2": [15], "(HER2)-positive": [16], "metastatic": [17, 64, 312], "breast": [18, 65, 313], "cancer": [19, 66, 314], "whose": [20], "disease": [21, 110, 275, 325, 353], "progresses": [22], "after": [23], "a": [26, 32, 35, 72, 320], "combination": [27], "of": [28, 48, 57, 104, 155, 214, 229, 237, 241, 257, 261, 281, 292, 300, 304, 324], "anti-HER2": [29], "antibodies": [30], "and": [31, 46, 71, 96, 127, 173, 221, 249, 254, 268, 289, 319, 354, 360], "taxane.We": [33], "conducted": [34], "phase": [36], "3,": [37], "multicenter,": [38], "open-label,": [39], "randomized": [40], "trial": [41], "to": [42, 122, 132, 150, 168, 178, 191, 212, 227], "compare": [43], "efficacy": [45], "safety": [47], "trastuzumab": [49, 58, 70, 125, 135, 171, 181, 219, 233, 247, 252, 286, 296, 318, 335, 342, 346], "deruxtecan": [50, 126, 172, 220, 248, 287, 336, 347], "(a": [51, 201], "HER2": [52], "antibody-drug": [53], "conjugate)": [54], "those": [56, 105, 230, 293, 332, 339], "in": [60, 207, 222, 279, 284, 290, 294], "HER2-positive": [63, 311], "previously": [67, 315], "treated": [68, 316], "taxane.": [73], "The": [74, 153, 235], "primary": [75], "end": [76, 89], "point": [77], "was": [78, 115, 163, 244, 266, 329, 348], "progression-free": [79], "survival": [80], "(as": [81], "determined": [82], "by": [83, 357], "blinded": [84], "independent": [85], "central": [86], "review);": [87], "secondary": [88], "points": [90], "included": [91], "overall": [92, 199], "survival,": [93], "objective": [94], "response,": [95], "safety.Among": [97], "524": [98], "randomly": [99], "assigned": [100], "patients,": [101], "percentage": [103, 154], "who": [106, 157, 217, 231, 333, 340], "were": [107, 158, 303], "alive": [108, 159], "without": [109], "progression": [111, 140, 326], "at": [112, 160], "12": [113, 161], "months": [114, 162], "75.8%": [116], "(95%": [117, 129, 165, 175, 209, 224], "confidence": [118], "interval": [119], "[CI],": [120], "69.8": [121], "80.7)": [123], "34.1%": [128], "CI,": [130, 148, 166, 176, 189, 210, 225], "27.7": [131], "40.5)": [133], "(hazard": [137, 183], "ratio": [138, 184], "or": [141, 203, 264, 276, 307, 327], "death": [142, 328], "from": [143], "any": [144, 242], "cause,": [145], "0.28;": [146], "95%": [147, 188], "0.22": [149], "0.37;": [151], "P<0.001).": [152], "94.1%": [164], "90.3": [167], "96.4)": [169], "85.9%": [174], "80.9": [177], "89.7)": [179], "death,": [186], "0.55;": [187], "0.36": [190], "0.86;": [192], "prespecified": [193], "significance": [194], "boundary": [195], "not": [196], "reached).": [197], "An": [198], "response": [200], "complete": [202], "partial": [204], "response)": [205], "occurred": [206, 278], "79.7%": [208], "74.3": [211], "84.4)": [213], "received": [218, 232, 334, 341], "34.2%": [223], "28.5": [226], "40.3)": [228], "emtansine.": [234, 343], "incidence": [236, 256], "drug-related": [238, 258, 272], "adverse": [239, 259], "events": [240, 260, 302], "grade": [243, 262, 305], "98.1%": [245], "86.6%": [250], "emtansine,": [253], "3": [263], "4": [265, 306], "45.1%": [267], "39.8%,": [269], "respectively.": [270], "Adjudicated": [271], "interstitial": [273, 351], "lung": [274, 352], "pneumonitis": [277], "10.5%": [280], "group": [288], "1.9%": [291], "group;": [298], "none": [299], "these": [301], "5.Among": [308], "taxane,": [321], "risk": [323], "lower": [330], "among": [331, 338], "than": [337], "Treatment": [344], "associated": [349], "pneumonitis.": [355], "(Funded": [356], "Daiichi": [358], "Sankyo": [359], "AstraZeneca;": [361], "DESTINY-Breast03": [362], "ClinicalTrials.gov": [363], "number,": [364], "NCT03529110.).": [365]}